J 2022

VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment

SALMANTON-GARCIA, Jon, Fiona A STEWART, Sarah HERINGER, Markela KONIORDOU, Elena ALVAREZ-BARCO et. al.

Základní údaje

Originální název

VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment

Autoři

SALMANTON-GARCIA, Jon (garant), Fiona A STEWART, Sarah HERINGER, Markela KONIORDOU, Elena ALVAREZ-BARCO, Christos D ARGYROPOULOS, Sophia C THEMISTOCLEOUS, Paula VALLE-SIMON, Orly SPIVAK, Lenka SOUČKOVÁ (203 Česká republika, domácí), Christina MERAKOU, Maria Amelia MENDONCA, Ruth Joanna DAVIS, Anna Maria AZZINI, Helena H ASKLING, Sirkka VENE, Van Damme PIERRE, Angela STEINBACH, George SHIAMAKKIDES, Danila SEIDEL, Ole F OLESEN, Evgenia NOULA, Alan MACKEN, Catarina LUIS, Janina LECKLER, Odile LAUNAY, Catherine ISITT, Margot HELLEMANS, Jesus FRIAS-INIESTA, Di Marzo ROMINA, Antonio J CARCAS, George BOUSTRAS, Alberto M BOROBIA, Imre BARTA, Kerstin ALBUS, Murat AKOVA, Jordi OCHANDO, Miriam COHEN-KANDLI, Rebecca Jane COX, Petr HUSA (203 Česká republika, domácí), Ligita JANCORIENE, Patrick MALLON, Laura MARQUES, Sibylle C MELLINGHOFF, Pontus NAUCLER, Evelina TACCONELLI, Krisztina TOTH, Theoklis E ZAOUTIS, Markus ZEITLINGER, Oliver A CORNELY a Zoi-Dorothea PANA

Vydání

Vaccine, OXFORD, ELSEVIER SCI LTD, 2022, 0264-410X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.500

Kód RIV

RIV/00216224:14110/22:00127302

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.vaccine.2022.05.022

UT WoS

000832911500003

Klíčová slova anglicky

SARS-CoV-2; Registry; Pandemic preparedness; Clinical trial; Volunteer; Vaccination campaign; COVID-19; Vaccination network

Štítky

14110214, 14110516, rivok

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 30. 11. 2022 14:12, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: The coronavirus disease 2019 (COVID-19) pandemic has evidenced the key role of vaccine design, obtention, production and administration to successfully fight against infectious diseases and to provide efficient remedies for the citizens. Although clinical trials were rapidly established during this pandemic, identifying suitable study subjects can be challenging. For this reason, the University Hospital Cologne established a volunteer registry for participation in clinical trials first in Germany, which has now been incorporated into the European VACCELERATE clinical trials network and grew to a European Volunteer Registry. As such, VACCELERATE's Volunteer Registry aims to become a common entry point for potential volunteers in future clinical trials in Europe. Methods: Interested volunteers who would like to register for clinical trials in the VACCELERATE Volunteer Registry can access the registration questionnaire via http://www.vaccelerate.eu/volunteer-registry. Potential volunteers are requested to provide their current country and area of residence, contact information, including first and last name and e-mail address, age, gender, comorbidities, previous SARS-CoV-2 infection and vaccination status, and maximum distance willing to travel to a clinical trial site. The registry is open to both adults and children, complying with national legal consent requirements. Results: As of May 2022, the questionnaire is available in 12 countries and 14 languages. Up to date, more than 36,000 volunteers have registered, mainly from Germany. Within the first year since its establishment, the VACCELERATE Volunteer Registry has matched more than 15,000 volunteers to clinical trials. The VACCELERATE Volunteer Registry will be launched in further European countries in the coming months. Conclusions: The VACCELERATE Volunteer Registry is an active single-entry point for European residents interested in COVID-19 clinical trials participation in 12 countries (i.e., Austria, Cyprus, Germany, Greece, Ireland, Lithuania, Norway, Portugal, Spain, Sweden and Turkey). To date, more than 15,000 registered individuals have been connected to clinical trials in Germany alone. The registry is currently in the implementation phase in 5 additional countries (i.e., Belgium, Czech Republic, Hungary, Israel and the Netherlands).

Návaznosti

101037867, interní kód MU
Název: VACCELERATE - European Corona Vaccine Trial Accelerator Platform (Akronym: VACCELERATE)
Investor: Evropská unie, VACCELERATE - European Corona Vaccine Trial Accelerator Platform, Health, demographic change and wellbeing (Societal Challenges)
Zobrazeno: 10. 11. 2024 17:15